Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-κB activation

Science

Volumn 331, Issue 6016, 2011, Pages 468-472

  Rosebeck, Shaun ^a   Madden, Lisa ^a,f   Jin, Xiaohong ^b   Gu, Shufang ^a   Apel, Ingrid J ^b   Appert, Alex ^c   Hamoudi, Rifat A ^c   Noels, Heidi ^d,e,g   Sagaert, Xavier ^d   Van Loo, Peter ^d,e   Baens, Mathijs ^d,e   Du, Ming Qing ^c   Lucas, Peter C ^b   McAllister Lucas, Linda M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR KAPPA B INDUCING KINASE; ONCOPROTEIN; ONCOPROTEIN API2 MALT1; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ADHESION; APOPTOSIS; CYTOLOGY; PROTEIN;

APOPTOSIS; ARTICLE; CHROMOSOME TRANSLOCATION 11; ENZYME ACTIVITY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

APOPTOSIS; B-LYMPHOCYTES; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; LYMPHOMA, B-CELL, MARGINAL ZONE; NF-KAPPA B; NF-KAPPA B P52 SUBUNIT; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 79251574621     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1198946     Document Type: Article

References (37)

1. P. G. Isaacson, M. Q. Du, Nat. Rev. Cancer 4, 644 (2004).
2. M. Thome, Nat. Rev. Immunol. 8, 495 (2008).
3. P. C. Lucas et al., J. Biol. Chem. 276, 19012 (2001).
4. L. Sun, L. Deng, C. K. Ea, Z. P. Xia, Z. J. Chen, Mol. Cell 14, 289 (2004).
5. P. C. Lucas et al., Oncogene 26, 5643 (2007).
6. H. Zhou, M. Q. Du, V. M. Dixit, Cancer Cell 7, 425 (2005).
7. Materials and methods are available as supporting material on Science Online.
8. T. D. Gilmore, Oncogene 25, 6680 (2006).
9. N. L. Malinin, M. P. Boldin, A. V. Kovalenko, D. Wallach, Nature 385, 540 (1997).
10. H. Y. Song, C. H. Régnier, C. J. Kirschning, D. V. Goeddel, M. Rothe, Proc. Natl. Acad. Sci. U.S.A. 94, 9792 (1997).
11. S. L. Petersen et al., Cancer Cell 12, 445 (2007).
12. E. Varfolomeev et al., Cell 131, 669 (2007).
13. J. E. Vince et al., Cell 131, 682 (2007).
14. B. Coornaert et al., Nat. Immunol. 9, 263 (2008).
15. F. Rebeaud et al., Nat. Immunol. 9, 272 (2008).
16. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
17. H. Noels et al., J. Biol. Chem. 282, 10180 (2007).
18. D. Sanchez-Izquierdo et al., Blood 101, 4539 (2003).
19. A. G. Uren et al., Mol. Cell 6, 961 (2000).
20. L. M. McAllister-Lucas, P. C. Lucas, Nat. Immunol. 9, 231 (2008).
21. G. Liao, M. Zhang, E. W. Harhaj, S.-C. Sun, J. Biol. Chem. 279, 26243 (2004).
22. S. Vallabhapurapu et al., Nat. Immunol. 9, 1364 (2008).
23. B. J. Zarnegar et al., Nat. Immunol. 9, 1371 (2008).
24. C. M. Annunziata et al., Cancer Cell 12, 115 (2007).
25. G. Bonizzi et al., EMBO J. 23, 4202 (2004).
26. J. L. Chen, A. Limnander, P. B. Rothman, Blood 111, 1677 (2008).
27. T. Enzler et al., Immunity 25, 403 (2006).
28. F. Guo, D. Weih, E. Meier, F. Weih, Blood 110, 2381 (2007).
29. R. T. Woodland et al., Blood 111, 750 (2008).
30. I. I. Witzel, L. F. Koh, N. D. Perkins, Biochem. Soc. Trans. 38, 217 (2010).
31. S. López-Giral et al., J. Leukoc. Biol. 76, 462 (2004).
32. Y. Nie et al., J. Exp. Med. 200, 1145 (2004).
33. M. Luftig et al., Proc. Natl. Acad. Sci. U.S.A. 101, 141 (2004).
34. See Materials and Methods in Supporting Online Materials for a description of the tumor collections nos. 1 and 2.
35. Y. Sasaki et al., Proc. Natl. Acad. Sci. U.S.A. 105, 10883 (2008).
36. M. Baens et al., Cancer Res. 66, 5270 (2006).
37. We thank M. Dyer for the SSK41 cells, R. Renne for the BJAB Tet-On cells, and G. Nunez for several expression plasmids. A Material Transfer Agreement is required for use of the SSK41 cells expressing API2-MALT1. Microarray data from MALT lymphoma tumor collections are Minimum Information About a Microarray Experiment (MIAME) compliant and are available online at the Gene Expression Omnibus (GEO) with accession number GSE25527 for collection no. 1 and accession number GSE25550 for collection no. 2 (www.ncbi.nlm.nih.gov/projects/geo/). L.M. is a recipient of the Nancy Newton Loeb Pediatric Cancer Research and Helen L. Kay Pediatric Cancer Research Awards and received support from National Institute of Child Health and Human Development, NIH, T32-HD07513. L.M. and S.R. were both supported by National Heart, Lung, and Blood Institute, NIH, T32-HL007622-21A2. M.B. is supported by grants from the Research Foundation - Flanders (FWO) and Belgian Foundation against Cancer. H.N. was an aspirant of the FWO-Vlaanderen. X.S. is a Senior Clinical Investigator of FWO-Vlaanderen, and P.V.L. is a postdoctoral researcher of the FWO. This work was supported by the Shirley K. Schlafer Foundation, the Elizabeth Caroline Crosby Fund, and grants from the University of Michigan Comprehensive Cancer Center (G007839), Leukemia and Lymphoma Research UK, and National Cancer Institute NIH (R01CA124540).